EUVIMEDEUVIMED entdecken
Crossref

Insights into omalizumab use in Auckland City Hospital's immunology 2023 chronic spontaneous urticaria cohort

Nathaniel Triffitt iD, Karen Lindsay

Internal Medicine Journal · 2026-04 · 56 (4) · 706-709

DOI: 10.1111/imj.70354 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Internal Medicine Journal, online erschienen am 24.02.2026. Verfasst von Nathaniel Triffitt und 1 weiteren Autor:innen. Beteiligte Einrichtung: Immunology Department, Auckland City Hospital, Auckland, New Zealand. Hauptthemen laut MEDLINE: Omalizumab, Chronic Urticaria, Anti-Allergic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This review of omalizumab use in chronic spontaneous urticaria (CSU) in Auckland City Hospital's immunology department in 2023 showed that rates of baseline investigations were high but did not clearly improve CSU management. There were associations between raised C‐reactive protein and higher doses of omalizumab, and lower C‐reactive protein and CSU remission. Most patients had angioedema and atopy. Median symptom duration was 5 years and the majority needed at least 1 year of omalizumab treatment. Fewer Māori/Pasifika patients in this cohort may reflect barriers to accessing health care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OmalizumabChronic UrticariaAnti-Allergic AgentsHumansNew ZealandFemaleMaleCohort StudiesC-Reactive ProteinAdultMiddle Aged

Stichwörter der Autor:innen

chronic spontaneous urticariaimmunologyomalizumab

Substanzen

OmalizumabAnti-Allergic AgentsC-Reactive Protein

Autor:innen und Institutionen

  • Immunology Department, Auckland City Hospital, Auckland, New Zealand.

ORCID-Profile: Nathaniel Triffitt

Zitieren

APA

Triffitt, N., & Lindsay, K. (2026). Insights into omalizumab use in Auckland City Hospital's immunology 2023 chronic spontaneous urticaria cohort. Internal Medicine Journal, 56(4), 706-709. https://doi.org/10.1111/imj.70354

Vancouver

Triffitt N, Lindsay K. Insights into omalizumab use in Auckland City Hospital's immunology 2023 chronic spontaneous urticaria cohort. Internal Medicine Journal. 2026;56(4):706-709. doi:10.1111/imj.70354

BibTeX
@article{Triffitt2026,
  author = {Triffitt, Nathaniel and Lindsay, Karen},
  title = {Insights into omalizumab use in Auckland City Hospital's immunology 2023 chronic spontaneous urticaria cohort},
  journal = {Internal Medicine Journal},
  year = {2026},
  volume = {56},
  number = {4},
  pages = {706--709},
  doi = {10.1111/imj.70354}
}
Kostenlos starten →